| Species |
Human |
| Protein Construction |
Complement C2 (Ala21-Leu752)
Accession # P06681-1 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its ability to cleave a colorimetric peptide substrate, NcarbobenzyloxyGlyArgThioBenzyl ester (ZGRSBzl), in the presence of 5,5'Dithiobis (2nitrobenzoic acid) (DTNB). The specific activity is >100 pmol/min/µg. Test result meets the standard. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
82.2 kDa (Pro form) |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 83-90 kDa (Pro form) based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Single nucleotide polymorphism (SNP) of complement component 2 (C2) has been found to be significantly associated with hepatocellular carcinoma (HCC). Significantly lower C2 expression was found at HCC compared to healthy controls, and C2 was associated with TNM stages. Higher C2 expression was significantly associated with better prognosis, and multivariate analysis showed that C2 was also an independent factor for the prognosis of HCC. |
| Synonyms |
Complement Component C2; C3/C5 convertase; C2; ARMD14; CO2 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
